Home Cart Sign in  
Chemical Structure| 1361390-56-8 Chemical Structure| 1361390-56-8

Structure of RR-11a
CAS No.: 1361390-56-8

Chemical Structure| 1361390-56-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RR-11a is a synthetic enzyme inhibitor of Legumain, an asparaginyl endopeptidase.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RR-11a

CAS No. :1361390-56-8
Formula : C24H28N6O10
M.W : 560.51
SMILES Code : C[C@@H](C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)NC([C@H](C)NC(OCC2=CC=CC=C2)=O)=O
MDL No. :MFCD31657423
InChI Key :OBTLSXIZYGMZRE-BWLFODOESA-N
Pubchem ID :88556687

Safety of RR-11a

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human bone marrow mesenchymal stromal cells (hBMSC-TERT) 50 µM 14 days To evaluate the inhibitory effect of RR-11a on legumain activity and its reversal of TGF-β1-induced inhibition of osteoblast maturation. Results showed that RR-11a significantly inhibited legumain activity and completely reversed the inhibitory effect of TGF-β1 on osteoblast maturation. Front Endocrinol (Lausanne). 2024 Sep 19;15:1445049
Mouse renal tubular epithelial cells (mRTECs) 100 nM 24 hours To evaluate the protective effect of RR-11a on hypoxia-induced cell death. Results showed that RR-11a pretreatment improved cell survival and reduced lipid peroxidation levels. Cell Death Dis. 2021 Jan 11;12(1):65

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice OCI-Ly3 xenograft DLBCL model Intraperitoneal injection 0.2 mg/kg Once daily for 12 days Inhibition of legumain activity significantly suppressed tumor growth, reduced angiogenesis, and increased collagen deposition. Sci Rep. 2016 Jul 28;6:30347
C57BL/6J mice Myocardial infarction model Intraperitoneal injection 20 mg/kg Once daily for 29 days To evaluate the effect of RR-11a on cardiac function and structural remodeling post-myocardial infarction. Results showed that RR-11a significantly improved cardiac function, reduced cardiac rupture rate, and attenuated left ventricular dilation and wall thinning. Cell Death Dis. 2020 Nov 26;11(11):1014
Mice Bilateral ischemia-reperfusion injury (IRI) model Intraperitoneal injection 20 mg/kg Single dose, observed up to 7 days post-IRI To evaluate the protective effect of RR-11a on IRI-induced acute kidney injury. Results showed that RR-11a treatment significantly reduced serum creatinine and BUN levels, improved tubular injury, and ameliorated ferroptosis markers. Cell Death Dis. 2021 Jan 11;12(1):65

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.92mL

1.78mL

0.89mL

17.84mL

3.57mL

1.78mL

 

Historical Records

Categories